These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 29365155)

  • 1. Comparison of Palivizumab-Like Antibody Binding to Different Conformations of the RSV F Protein in RSV-Infected Adult Hematopoietic Cell Transplant Recipients.
    Ye X; Iwuchukwu OP; Avadhanula V; Aideyan LO; McBride TJ; Ferlic-Stark LL; Patel KD; Piedra FA; Shah DP; Chemaly RF; Piedra PA
    J Infect Dis; 2018 Mar; 217(8):1247-1256. PubMed ID: 29365155
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antigenic Site-Specific Competitive Antibody Responses to the Fusion Protein of Respiratory Syncytial Virus Were Associated With Viral Clearance in Hematopoietic Cell Transplantation Adults.
    Ye X; Iwuchukwu OP; Avadhanula V; Aideyan LO; McBride TJ; Ferlic-Stark LL; Patel KD; Piedra FA; Shah DP; Chemaly RF; Piedra PA
    Front Immunol; 2019; 10():706. PubMed ID: 30984206
    [No Abstract]   [Full Text] [Related]  

  • 3. Humoral and Mucosal Antibody Response to RSV Structural Proteins in RSV-Infected Adult Hematopoietic Cell Transplant (HCT) Recipients.
    Ye X; Iwuchukwu OP; Avadhanula V; Aideyan LO; McBride TJ; Henke DM; Patel KD; Piedra FA; Angelo LS; Shah DP; Chemaly RF; Piedra PA
    Viruses; 2021 May; 13(6):. PubMed ID: 34073490
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antigenic Fingerprinting of Respiratory Syncytial Virus (RSV)-A-Infected Hematopoietic Cell Transplant Recipients Reveals Importance of Mucosal Anti-RSV G Antibodies in Control of RSV Infection in Humans.
    Fuentes S; Hahn M; Chilcote K; Chemaly RF; Shah DP; Ye X; Avadhanula V; Piedra PA; Golding H; Khurana S
    J Infect Dis; 2020 Feb; 221(4):636-646. PubMed ID: 31745552
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Respiratory syncytial virus fusion nanoparticle vaccine immune responses target multiple neutralizing epitopes that contribute to protection against wild-type and palivizumab-resistant mutant virus challenge.
    Gilbert BE; Patel N; Lu H; Liu Y; Guebre-Xabier M; Piedra PA; Glenn G; Ellingsworth L; Smith G
    Vaccine; 2018 Dec; 36(52):8069-8078. PubMed ID: 30389195
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of a Prefusion Respiratory Syncytial Virus F-Specific Monoclonal Antibody That Provides Greater
    Zhao M; Zheng ZZ; Chen M; Modjarrad K; Zhang W; Zhan LT; Cao JL; Sun YP; McLellan JS; Graham BS; Xia NS
    J Virol; 2017 Aug; 91(15):. PubMed ID: 28539438
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Respiratory syncytial virus prefusogenic fusion (F) protein nanoparticle vaccine: Structure, antigenic profile, immunogenicity, and protection.
    Patel N; Massare MJ; Tian JH; Guebre-Xabier M; Lu H; Zhou H; Maynard E; Scott D; Ellingsworth L; Glenn G; Smith G
    Vaccine; 2019 Sep; 37(41):6112-6124. PubMed ID: 31416644
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structural basis for nonneutralizing antibody competition at antigenic site II of the respiratory syncytial virus fusion protein.
    Mousa JJ; Sauer MF; Sevy AM; Finn JA; Bates JT; Alvarado G; King HG; Loerinc LB; Fong RH; Doranz BJ; Correia BE; Kalyuzhniy O; Wen X; Jardetzky TS; Schief WR; Ohi MD; Meiler J; Crowe JE
    Proc Natl Acad Sci U S A; 2016 Nov; 113(44):E6849-E6858. PubMed ID: 27791117
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of respiratory syncytial virus fusion protein from clinical isolates of Korean children in palivizumab era, 2009-2015.
    Choi SH; Park KS; Kim YJ
    J Infect Chemother; 2019 Jul; 25(7):514-519. PubMed ID: 30885457
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Respiratory syncytial virus-neutralizing monoclonal antibodies motavizumab and palivizumab inhibit fusion.
    Huang K; Incognito L; Cheng X; Ulbrandt ND; Wu H
    J Virol; 2010 Aug; 84(16):8132-40. PubMed ID: 20519399
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Packaging and Prefusion Stabilization Separately and Additively Increase the Quantity and Quality of Respiratory Syncytial Virus (RSV)-Neutralizing Antibodies Induced by an RSV Fusion Protein Expressed by a Parainfluenza Virus Vector.
    Liang B; Ngwuta JO; Herbert R; Swerczek J; Dorward DW; Amaro-Carambot E; Mackow N; Kabatova B; Lingemann M; Surman S; Yang L; Chen M; Moin SM; Kumar A; McLellan JS; Kwong PD; Graham BS; Schaap-Nutt A; Collins PL; Munir S
    J Virol; 2016 Nov; 90(21):10022-10038. PubMed ID: 27581977
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structural basis for immunization with postfusion respiratory syncytial virus fusion F glycoprotein (RSV F) to elicit high neutralizing antibody titers.
    Swanson KA; Settembre EC; Shaw CA; Dey AK; Rappuoli R; Mandl CW; Dormitzer PR; Carfi A
    Proc Natl Acad Sci U S A; 2011 Jun; 108(23):9619-24. PubMed ID: 21586636
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of Epitope-Specific Anti-Respiratory Syncytial Virus (Anti-RSV) Antibody Responses after Natural Infection and after Vaccination with Formalin-Inactivated RSV.
    Widjaja I; Wicht O; Luytjes W; Leenhouts K; Rottier PJM; van Kuppeveld FJM; Haijema BJ; de Haan CAM
    J Virol; 2016 Jul; 90(13):5965-5977. PubMed ID: 27099320
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potent Human Single-Domain Antibodies Specific for a Novel Prefusion Epitope of Respiratory Syncytial Virus F Glycoprotein.
    Xun G; Song X; Hu J; Zhang H; Liu L; Zhang Z; Gong R
    J Virol; 2021 Aug; 95(18):e0048521. PubMed ID: 34160257
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced Neutralizing Antibody Response Induced by Respiratory Syncytial Virus Prefusion F Protein Expressed by a Vaccine Candidate.
    Liang B; Surman S; Amaro-Carambot E; Kabatova B; Mackow N; Lingemann M; Yang L; McLellan JS; Graham BS; Kwong PD; Schaap-Nutt A; Collins PL; Munir S
    J Virol; 2015 Sep; 89(18):9499-510. PubMed ID: 26157122
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Infection with novel respiratory syncytial virus genotype Ontario (ON1) in adult hematopoietic cell transplant recipients, Texas, 2011-2013.
    Avadhanula V; Chemaly RF; Shah DP; Ghantoji SS; Azzi JM; Aideyan LO; Mei M; Piedra PA
    J Infect Dis; 2015 Feb; 211(4):582-9. PubMed ID: 25156562
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Age-Specific Profiles of Antibody Responses against Respiratory Syncytial Virus Infection.
    Jounai N; Yoshioka M; Tozuka M; Inoue K; Oka T; Miyaji K; Ishida K; Kawai N; Ikematsu H; Kawakami C; Shimizu H; Mori M; Ishii KJ; Takeshita F
    EBioMedicine; 2017 Feb; 16():124-135. PubMed ID: 28111238
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Potential of Prefusion RSV F-specific Antibodies.
    Rossey I; McLellan JS; Saelens X; Schepens B
    Trends Microbiol; 2018 Mar; 26(3):209-219. PubMed ID: 29054341
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human respiratory syncytial virus: pathogenesis, immune responses, and current vaccine approaches.
    Taleb SA; Al Thani AA; Al Ansari K; Yassine HM
    Eur J Clin Microbiol Infect Dis; 2018 Oct; 37(10):1817-1827. PubMed ID: 29876771
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Phase 2 randomized, observer-blind, placebo-controlled, dose-ranging trial of aluminum-adjuvanted respiratory syncytial virus F particle vaccine formulations in healthy women of childbearing age.
    August A; Glenn GM; Kpamegan E; Hickman SP; Jani D; Lu H; Thomas DN; Wen J; Piedra PA; Fries LF
    Vaccine; 2017 Jun; 35(30):3749-3759. PubMed ID: 28579233
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.